how 4,895 daltons of retatrutide get past your stomach

so is this just expensive water?

retatrutide is 4,895 daltons. lipinski's rule of 5 says nothing over 500 da gets absorbed orally. so when IonPeptide shipped a dropper bottle of oral retatrutide, the first reaction was the same one anyone in r/BodyHackGuide is about to have: this can't possibly work.

then we read the Kossovsky 1995 paper. then a stack of 13 others. the rule isn't wrong — it just applies to free peptide bouncing around stomach acid, not peptide adsorbed onto a 200-nanometer ceramic sphere coated in trehalose and routed through your lymphatic system. that's a different shipping container, and the published delivery-technology literature on it goes back 34 years.

if you saw the ion launch and thought "yeah right" — same. then we kept reading. this is what we found.

AQASOMEs, in one paragraph

AQASOMEs are self-assembled three-layer nanoparticles, 60 to 300 nanometers across, designed for delivering fragile bioactive molecules like peptides through hostile environments like the gut. Nir Kossovsky and colleagues described them in the early 1990s. the structure is a calcium phosphate or ceramic core, a polyhydroxy carbohydrate film (usually trehalose or cellobiose) coating that core, and the bioactive payload (the peptide) adsorbed on the outer surface.

why lipinski's rule kills most oral peptides

Christopher Lipinski's "rule of 5" PMID:11259830 looked at Pfizer's clinical-stage drugs and noticed orally bioavailable molecules almost always weighed under 500 daltons. for free, unprotected peptide in a glass of water, the rule is right. three things go wrong: stomach acid at ph 1.5 to 3.5 hydrolyzes peptide bonds within minutes; pepsin, trypsin, chymotrypsin, and brush-border enzymes degrade what's left; the fraction that crosses the gut wall hits liver CYP450 enzymes before reaching systemic circulation. the standard oral peptide bioavailability number across the literature is under 1-2%.

rybelsus (oral semaglutide, 4,113 Da — barely smaller than retatrutide) is the proof that the rule of 5 can be partially defeated. its FDA label confirms 0.4-2% bioavailability via SNAC (salcaprozate sodium) chaperone tech (Buckley et al. 2018, PMID:30429357). that miserable number turned into a multi-billion-dollar drug. AQASOMEs go after the same problem from a different angle entirely.

three layers, built inside out

the architecture is a russian-doll. you start at the core and build outward. each layer has a specific job in keeping the peptide alive long enough to get absorbed.

the canonical proof-of-concept is insulin. Cherian 2000 demonstrated slower release and prolonged blood-glucose-lowering activity from insulin-AQASOMEs vs free insulin in rats. the umbrella review by Umashankar 2009 PMID:19931422 and the 2020 protein/peptide AQASOME review PMID:32337668 summarize the case across insulin, hemoglobin, serratiopeptidase, and antigen delivery.

the three things that kill normal oral peptides (and how AQASOMEs dodge each one)

barrier 1: stomach acid. free peptide bonds hydrolyze at ph 1.5-3.5. the trehalose/cellobiose shell vitrifies into a glassy layer that doesn't dissolve until it hits the higher ph of the small intestine.

barrier 2: proteases. pepsin, trypsin, chymotrypsin, brush-border peptidases need physical access to the peptide bond to cleave it. AQASOMEs put the peptide on the outer surface of a 60-300 nm sphere, sterically blocked from protease docking by the surrounding carbohydrate matrix.

barrier 3: first-pass liver metabolism. this is the one that matters most. free peptide absorbed across the gut wall flows into the hepatic portal vein — liver first, everything else second. nanoparticles in the 60-300 nm range take a different route entirely: m-cells in peyer's patches package them into chylomicrons and route them through the intestinal lymphatic system, which empties into systemic circulation via the thoracic duct. the liver only sees the drug after every other tissue has had a turn.

key citations: Shakweh 2004 PMID:16296726 on peyer's patch uptake, Managuli 2018 PMID:30025212 on intestinal lymphatic targeting, the 2017 review (PMC6527526) on the m-cell route.

oral retatrutide vs rybelsus — why the ceiling is different

retatrutide is Eli Lilly's triple agonist (GIP, GLP-1, glucagon). 4,895 daltons. by every reported metric, the most aggressive weight-loss molecule currently in clinical development.

phase 2 obesity (12 mg, 48 wk): -24.2% PMID:37366315. phase 2 T2D HbA1c reduction: -2.2% PMID:37385280. phase 2a MASH liver fat: -86% PMID:38858523. phase 3 TRIUMPH-4 (68 wk): -28.7% (Lilly Dec 2025).

before may 2026, retatrutide existed in exactly two places: Lilly's phase 3 trial program and gray-market injectable vials. the AQASOME formulation is the first oral version.

mechanically, AQASOME has a higher bioavailability ceiling than rybelsus's snac chaperone tech because it bypasses first-pass entirely instead of partially. on published evidence specifically for retatrutide-in-AQASOME, the per-compound bioavailability number has not been peer-reviewed in pk studies as of may 2026. the architecture is published. the route is published. the peptide-in-AQASOME category is published. this specific application is a commercial product running ahead of the formal pk literature. price it accordingly.

the 11 peptides i've been looking into

this is the actual list of compounds where the AQASOME carrier solves a real delivery problem. eleven molecules across five use case categories — metabolic, recovery, gh-axis, aesthetic, libido — plus one small-molecule exercise mimetic that doesn't fit the peptide category at all (slu-pp-332). each one is here for a specific reason. some you've heard of, some you haven't.

full lineup (with mechanism notes + PMIDs)

the obvious counterarguments

how to actually use it

ion's published protocol — illustrated:

track from day 1: subjective energy, sleep, recovery; baseline labs (fasted glucose, lipid panel, ALT/AST, hsCRP, IGF-1 if running gh-axis compounds); body weight + waist for retatrutide and aod-9604; skin and hair photos for glow.

where the data ends and our guess begins

per-compound oral bioavailability for this specific AQASOME formulation is not in peer-reviewed pk literature as of may 2026. the underlying technology is published. long-term safety data for daily oral AQASOME dosing at scale doesn't exist yet. systemic exposure from an oral drop is almost certainly lower than the equivalent injectable mg dose — don't assume 1:1. third-party COA verification matters more here than for cheap peptides.

FAQ

do oral peptides actually work?

free peptide in a capsule, no. wrapped in the right delivery system, yes. rybelsus gets 0.4-2% bioavailability via snac chaperone tech and is a multi-billion-dollar product. insulin-in-AQASOMEs shows systemic activity in rats. insulin-in-cyanoacrylate-nanoparticles hits 36% oral BA vs 22% for IV free drug.

how can a peptide over 500 daltons be orally bioavailable?

lipinski's rule predicts absorption of free small molecules. it doesn't account for nanoparticle delivery via m-cells in peyer's patches and lymphatic uptake. cyclosporine (1,202 Da), rybelsus (4,113 Da), and monoclonal antibodies (~150,000 Da) all violate the rule and work clinically.

what is AQASOME nanotechnology?

AQASOMEs are self-assembled 60-300 nm nanoparticles with three layers: calcium phosphate or ceramic core, polyhydroxy oligomer carbohydrate film (trehalose or cellobiose), and bioactive payload adsorbed on the outer surface. first described by Kossovsky et al. in the early 1990s.

how does oral retatrutide compare to rybelsus?

rybelsus uses SNAC (salcaprozate sodium) to chaperone free semaglutide across the stomach lining (0.4-2% BA per FDA label). oral retatrutide uses an AQASOME carrier — a nanoparticle that bypasses acid, proteases, and first-pass via m-cell lymphatic uptake. mechanically the AQASOME route has a higher BA ceiling because it skips first-pass entirely instead of partially. per-compound PK data for the AQASOME-retatrutide formulation isn't in peer-reviewed literature yet.

what's the difference between glow and wolverine?

both contain bpc-157 + tb-500 for systemic recovery and tissue repair. glow adds ghk-cu (copper peptide) for skin density, hair density, and collagen upregulation — the cosmetic version. wolverine is the orthopedic/injury recovery version.

if you want to try this — here's where

the only consumer brand commercializing AQASOME architecture across a full lineup right now is IonPeptide. they shipped 11 SKUs in may 2026. BHG is a launch affiliate — clicking through one of the links below applies our ref code reddit15 at checkout (discount for you, commission to BHG). disclosed in full at the bottom of the page.

further reading on BHG

• injectable retatrutide stack
• standalone retatrutide protocol
• wolverine pair comparison
• verify any oral product's COA
• retatrutide vs tirzepatide
• live retatrutide prices
• peptide vendor trust scorecard

disclosure: ion peptide is one of BHG's launch affiliate partners. /go/ion-* links are tracked and use the ref code reddit15 — applies a discount for you at checkout and pays BHG a commission. IonPeptide sent samples for evaluation. not a paid post — the body copy was written before the affiliate relationship started.

educational, not medical advice. peptides discussed are research compounds in most jurisdictions and are not FDA-approved for the uses described. retatrutide is investigational and only legally available via clinical trials as of may 2026. talk to a clinician before starting any peptide protocol.

the BHG team